Edition:
United Kingdom

AMAG Pharmaceuticals Inc (AMAG.OQ)

AMAG.OQ on NASDAQ Stock Exchange Global Select Market

10.03USD
23 Aug 2019
Change (% chg)

$-0.26 (-2.53%)
Prev Close
$10.29
Open
$10.29
Day's High
$10.54
Day's Low
$10.00
Volume
240,343
Avg. Vol
332,360
52-wk High
$25.15
52-wk Low
$6.81

Latest Key Developments (Source: Significant Developments)

Caligan Partners Reports A 10.3% Stake In Amag Pharmaceuticals As Of Aug. 6
Thursday, 15 Aug 2019 

Aug 15 (Reuters) - Caligan Partners LP::CALIGAN PARTNERS LP - BELIEVE SECURITIES OF AMAG PHARMACEUTICALS ARE UNDERVALUED & REPRESENT AN ATTRACTIVE INVESTMENT OPPORTUNITY.CALIGAN PARTNERS LP REPORTS A 10.3% STAKE IN AMAG PHARMACEUTICALS <<>> AS OF AUG. 6 - SEC FILING .CALIGAN PARTNERS - MAY DEVELOP PLANS OR MAKE PROPOSALS REGARDING POTENTIAL STRATEGIC REVIEW OR SALE PROCESS INVOLVING AMAG OR ITS ASSETS.CALIGAN PARTNERS LP - INTEND TO COMMUNICATE WITH AMAG PHARMACEUTICALS' MANAGEMENT & BOARD ABOUT RANGE OF OPERATIONAL & STRATEGIC MATTERS.CALIGAN PARTNERS - MAY DEVELOP PLANS, MAKE PROPOSALS REGARDING AMAG'S MANAGEMENT, COMPOSITION OF BOARD OF DIRECTORS.CALIGAN PARTNERS - MAY DEVELOP PLANS, MAKE PROPOSALS REGARDING AMAG'S DIVIDEND POLICY.CALIGAN PARTNERS LP - INTEND TO COMMUNICATE WITH AMAG PHARMACEUTICALS' OTHER SHAREHOLDERS OR POTENTIAL ACQUIRERS, SERVICE PROVIDERS, FINANCING SOURCES.  Full Article

AMAG Pharmaceuticals Q2 Revenue $78.1 Million Versus $146.3 Million
Wednesday, 7 Aug 2019 

Aug 7 (Reuters) - AMAG Pharmaceuticals Inc ::AMAG PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q2 REVENUE $78.1 MILLION VERSUS $146.3 MILLION.Q2 REVENUE ESTIMATE $92 MILLION -- REFINITIV IBES DATA.2019 FINANCIAL GUIDANCE LOWERED: EXITING MAKENA INTRAMUSCULAR MARKET AND REMOVING MILESTONE REVENUE.VYLEESI ON-TRACK FOR NATIONAL LAUNCH IN SEPTEMBER.SEES 2019 TOTAL REVENUE $325 MILLION - $355 MILLION.SEES 2019 OPERATING LOSS $286 MILLION - $276 MILLION.  Full Article

AMAG Pharmaceuticals Announces Second Quarter 2019 Financial Results
Wednesday, 7 Aug 2019 

Aug 7 (Reuters) - AMAG Pharmaceuticals Inc ::AMAG PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q2 REVENUE $41 MILLION.Q2 REVENUE ESTIMATE $92 MILLION -- REFINITIV IBES DATA.2019 FINANCIAL GUIDANCE LOWERED: EXITING MAKENA INTRAMUSCULAR MARKET AND REMOVING MILESTONE REVENUE.VYLEESI ON-TRACK FOR NATIONAL LAUNCH IN SEPTEMBER.SEES 2019 TOTAL REVENUE $325 MILLION - $355 MILLION.SEES 2019 OPERATING LOSS $286 MILLION - $276 MILLION.  Full Article

AMAG Pharmaceuticals Says Q1 Loss Per Share $3.54 From Cont Ops
Tuesday, 7 May 2019 

May 7 (Reuters) - AMAG Pharmaceuticals Inc ::REPORTS Q1 2019 REVENUE $75.8 MILLION.AMAG PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q1 LOSS PER SHARE $3.54 FROM CONTINUING OPERATIONS.Q1 REVENUE $75.8 MILLION VERSUS REFINITIV IBES ESTIMATE OF $90.1 MILLION.Q1 EARNINGS PER SHARE ESTIMATE $-0.26 -- REFINITIV IBES DATA.REAFFIRMED 2019 FINANCIAL GUIDANCE.AS OF MARCH 31, 2019, COMPANY'S CASH AND INVESTMENTS TOTALED $266.5 MILLION, AND LONG-TERM TOTAL DEBT TOTALED $320.0 MILLION.  Full Article

AMAG Pharmaceuticals Reports Results From Prolong Trial Evaluating Makena
Friday, 8 Mar 2019 

March 8 (Reuters) - AMAG Pharmaceuticals Inc ::AMAG PHARMACEUTICALS ANNOUNCES TOPLINE RESULTS FROM THE PROLONG TRIAL EVALUATING MAKENA® (HYDROXYPROGESTERONE CAPROATE INJECTION).AMAG PHARMA - PROLONG TRIAL DID NOT DEMONSTRATE A STATISTICALLY SIGNIFICANT DIFFERENCE BETWEEN TREATMENT AND PLACEBO ARMS FOR CO-PRIMARY ENDPOINTS.AMAG PHARMACEUTICALS INC - PLAN TO CONDUCT ADDITIONAL SUB-GROUP ANALYSES OF PROLONG DATA.  Full Article

AMAG Reports Fourth Quarter And Full Year 2018 Results
Thursday, 7 Feb 2019 

Feb 7 (Reuters) - AMAG Pharmaceuticals Inc ::AMAG REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS AND PROVIDES COMPANY UPDATE.Q4 REVENUE $88.1 MILLION VERSUS REFINITIV IBES ESTIMATE OF $96.5 MILLION.REAFFIRMS 2019 FINANCIAL GUIDANCE AND ANNOUNCES CONSOLIDATION OF WOMEN'S HEALTH AND MATERNAL HEALTH SALES FORCES.FY2018 EARNINGS PER SHARE VIEW $-5.71, REVENUE VIEW $484.7 MILLION -- REFINITIV IBES DATA.EXPECTS TO RECORD A ONE-TIME RESTRUCTURING CHARGE OF APPROXIMATELY $6 MILLION IN Q1 OF 2019..QTRLY LOSS PER SHARE $0.64.  Full Article

Palatin Technologies Say FDA Has Extended Prescription Drug User Fee Act Date For Vyleesi By Three Months
Monday, 7 Jan 2019 

Jan 7 (Reuters) - AMAG Pharmaceuticals Inc ::PALATIN TECHNOLOGIES - FDA HAS EXTENDED THE PRESCRIPTION DRUG USER FEE ACT DATE FOR VYLEESI BY THREE MONTHS TO JUNE 23, 2019..PALATIN TECHNOLOGIES - FDA-REQUESTED FREQUENT-DOSING STUDY WITH PREMENOPAUSAL VOLUNTEERS ASSESSING SHORT TERM DAILY USE OF VYLEESI HAS BEEN INITIATED.PALATIN TECHNOLOGIES INC - STUDY RESULTS ARE ANTICIPATED TO BE SUBMITTED TO THE FDA PRIOR TO THE UPDATED PDUFA DATE OF JUNE 23, 2019..  Full Article

AMAG Pharmaceuticals Announces Preliminary 2018 Results
Monday, 7 Jan 2019 

Jan 7 (Reuters) - AMAG Pharmaceuticals Inc ::AMAG PHARMACEUTICALS ANNOUNCES PRELIMINARY 2018 FINANCIAL RESULTS AND PROVIDES 2019 FINANCIAL GUIDANCE.SEES FY 2018 REVENUE $471 MILLION TO $476 MILLION.SEES Q4 2018 REVENUE $85 MILLION TO $90 MILLION.FY2018 REVENUE VIEW $491.3 MILLION -- REFINITIV IBES DATA.Q4 REVENUE VIEW $101.8 MILLION -- REFINITIV IBES DATA.  Full Article

AMAG Pharmaceuticals Says Under Deal With Perosphere, The Company Is Obligated To Pay Future Contingent Consideration Of Up To $365 Mln
Thursday, 13 Dec 2018 

Dec 13 (Reuters) - AMAG Pharmaceuticals Inc ::AMAG PHARMACEUTICALS INC - UNDER DEAL WITH PEROSPHERE, THE COMPANY IS OBLIGATED TO PAY FUTURE CONTINGENT CONSIDERATION OF UP TO $365 MILLION.AMAG PHARMACEUTICALS INC - COMPANY INTENDS TO FUND THE UPFRONT MERGER CONSIDERATION FROM CASH ON HAND..  Full Article

AMAG Pharmaceuticals To Acquire Perosphere Pharmaceuticals
Thursday, 13 Dec 2018 

Dec 13 (Reuters) - AMAG Pharmaceuticals Inc ::AMAG PHARMACEUTICALS ENTERS INTO DEFINITIVE MERGER AGREEMENT TO ACQUIRE PEROSPHERE PHARMACEUTICALS.AMAG PHARMACEUTICALS INC - AMAG WILL PAY PEROSPHERE EQUITYHOLDERS $50 MILLION.AMAG PHARMACEUTICALS INC - AMAG WILL ASSUME $12 MILLION UNDER A TERM LOAN AND UP TO $6.2 MILLION OF PEROSPHERE'S OTHER LIABILITIES.AMAG PHARMACEUTICALS INC - CIRAPARANTAG HAS BEEN WELL TOLERATED IN CLINICAL TRIALS.AMAG PHARMACEUTICALS INC - PEROSPHERE EQUITYHOLDERS WILL BE ELIGIBLE TO RECEIVE REGULATORY MILESTONES OF UP TO $140 MILLION.AMAG PHARMACEUTICALS INC - PEROSPHERE EQUITYHOLDERS ARE ALSO ELIGIBLE TO RECEIVE COMMERCIAL SALES MILESTONE PAYMENTS OF UP TO AN AGGREGATE OF $225 MILLION.AMAG PHARMACEUTICALS INC - FIRST COMMERCIAL SALES MILESTONE PAYMENT OF $20 MILLION WOULD BE PAYABLE UPON ACHIEVING ANNUAL NET SALES OF $100 MILLION.AMAG PHARMACEUTICALS INC - PEROSPHERE EQUITYHOLDERS ARE ALSO ELIGIBLE TO RECEIVE COMMERCIAL SALES MILESTONE PAYMENTS OF UP TO AN AGGREGATE OF $225 MILLION.AMAG PHARMACEUTICALS INC - DO NOT CHANGE AMAG'S PRELIMINARY VIEW OF 2019 NEGATIVE ADJUSTED EBITDA OF APPROXIMATELY $50 MILLION.AMAG PHARMACEUTICALS - COSTS EXPECTED TO BE INCURRED IN 2019 TO ADVANCE NEW PIPELINE ASSET DO NOT CHANGE PREL VIEW OF 2019 NEGATIVE ADJUSTED EBITDA.AMAG PHARMA - IF SOME CLINICAL MILESTONES ARE MET, CIRAPARANTAG PHASE 3 PROGRAM WILL BE PARTIALLY FUNDED BY EXISTING AGREEMENT WITH GLOBAL PHARMA CO.  Full Article

UPDATE 1-Amag's female libido injectable therapy to sell at $899

Aug 6 Amag Pharmaceuticals Inc's treatment to boost sexual desire in premenopausal women will be offered at $899 and is the only injectable drug on the market for hypoactive sexual desire disorder (HSDD).